The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a novel biomarker reflecting inflammation, nutrition, and immune status, and its potential clinical significance and prognostic role in patients with rheumatoid arthritis (RA) has not been reported.

Disease Activity (DA) monitoring is a standard of care in Rheumatoid Arthritis (RA). There is demand for achieving this through Patient Reported Outcome Measures (PROMs). The aim of this study was to determine which items could be used to measure the construct of RA DA, by analysing legacy PROMs, using Rasch measurement theory (RMT) analyses.

Immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) are characterized by weakness, hyperCKemia, associated autoantibodies, and varying extramuscular manifestations. Muscle MRI, currently subordinate to histopathology and serology in idiopathic inflammatory myopathy (IIM) classification, has an evolving role. Our study aims to define thigh muscle MRI involvement in IMNM and DM by direct comparison.

Early initiation of effective treatment is associated with positive long-term prognosis for patients with rheumatoid arthritis (RA). Currently, there are no biomarkers in clinical use to predict treatment response. A predictor of treatment response may be the B-cell compartment, as this is altered in RA patients, making it a potential candidate for predicting treatment response. In this study, we sought to identify B-cell subset(s) at diagnosis that might be associated with Clinical Disease Activity Index (CDAI) remission at 24-week follow-up.

This study aimed to evaluate the predictability of the homozygous M694V genotype in pediatric familial Mediterranean fever (FMF) patients and to develop a clinical scoring system to enhance disease management strategies.

Emerging evidence suggests that post-traumatic stress disorder (PTSD) may increase susceptibility to autoimmune diseases, including systemic lupus erythematosus (SLE). PTSD-related immune dysregulation is hypothesized to heighten vulnerability to autoimmunity. This systematic review sought to evaluate the relationship between PTSD and the risk of developing SLE, as well as explore potential shared genetic predispositions.

The tremendous size of the 2013-2016 West African outbreak of Ebola virus disease (EVD) resulted in a sizeable population of survivors, many reporting short-term sequelae such as arthralgia and myalgia. We aimed to examine the occurrence of chronic musculoskeletal (MS) pain among survivors.

Fatigue is a prominent symptom in patients with psoriatic arthritis (PsA). There was a wide variety of statistics previously reported on fatigue prevalence in patients. This systematic review examined the current literature to derive the overall prevalence of fatigue and risk factors in PsA patients.

We evaluated drug retention rates to compare the effectiveness of Janus kinase (JAK) inhibitors vs. tumour necrosis factor inhibitor (TNFi) biologics and non-TNFi biologics in biologics-naïve rheumatoid arthritis (RA) patients, and assessed intra-class differences among JAK inhibitors.

To determine systemic lupus erythematosus (SLE) endotypes according to B cell immunophenotyping and serological profile and assess endotypes' response to belimumab.

Systemic sclerosis (SSc) and Sjögren's disease (SjD) are characterized by systemic inflammation. Although for both entities lymphocyte involvement is reported, the contribution of T cell responses to lung manifestation of SSc and SjD remains elusive. Therefore, we aimed for systematically investigating T cell responses in blood and lungs of patients with SSc or with SjD.

This study examines the influence of pharmacological treatments on foot functionality in patients with rheumatoid arthritis over a five-year period. A longitudinal analysis categorized patients into different treatment groups, assessing their foot function using the Foot Function Index (FFI) at the start and end of the study. The groups are based on their pharmacological treatment. Pharmacological treatment groups were categorized into: I methotrexate (MTX), II MTX plus biological treatments (including all variables), III biological treatment alone, and IV a miscellaneous group comprising patients with diverse treatments, including patients for whom various drugs had failed or who had not achieved remission with pharmacological treatment. The study included 206 RA patients with an average age of 58.32 years and a disease evolution of 15.28 years. The analysis of the FFI in total and across its domains of pain, disability, and activity revealed significant differences only in the pain domain (p = 0.011), with a trend toward worsening over time observed in the other domains. Notably, MTX treatment showed improvement in the pain domain (decreasing from 45.76 in 2018 to 40.43 in 2023). Findings suggest that while pharmacological treatments are essential in managing rheumatoid arthritis, their impact on foot function is limited, with MTX demonstrating the most significant benefit in terms of pain reduction.

NETs involvement in antiphospholipid syndrome (APS) pathogenesis is known, but the role of anti-β2glycoprotein I antibodies (aβ2GPI)-induced NETs in triggering a procoagulant and proinflammatory phenotype in endothelial cells (EC) remains to be evaluated. This study investigated whether NET-aβ2GPI can activate ECs and whether NET-aβ2GPI and NET-PMA have different proteomic profiles.

IgA vasculitis is a predominantly pediatric autoimmune disease characterized by IgA deposit in small vessels. Chronic myelomonocytic leukemia (CMML) is a rare hematological malignancy classified within myelodysplastic syndromes. Here, we present a previously unrecognized case of CMML associated with IgA vasculitis. A 62-year-old woman presented with necrotic and infiltrated purpura and mild arthralgia, primarily affecting the knees and wrists, without gastrointestinal or kidney involvement. A comprehensive screening for other etiologies was unremarkable. Blood tests showed an increase of monocyte count and circulating monocyte phenotyping was consistent with CMML. Bone marrow analysis showed no blast cells or karyotypic abnormalities. Genetic testing identified an NRAS mutation. Autoantibody screening and viral serologies were negative. A skin biopsy revealed small-vessel vasculitis with IgA immune deposits. CMML can be associated with autoimmune diseases, such as polyarteritis nodosa and cutaneous leukocytoclastic vasculitis. However, this is the first report of IgA vasculitis occurring in the context of low risk CMML.

Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease in which a significant proportion of patients remain refractory to existing therapies. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) initiated a project aimed at unraveling the reasons for treatment failures in PsA, culminating in the establishment of definitions for Difficult-to-Treat PsA (D2T-PsA) and Complex-to-Manage PsA (C2M-PsA). This study explores patient perspectives on treatment-resistant PsA, incorporating a broader patient perspective into the overarching GRAPPA project.